To include your compound in the COVID-19 Resource Center, submit it here.

Looking beyond Avastin

Doctors look ahead to new treatment options for metastatic breast cancer

As clinicians reduce their use of Avastin bevacizumab for metastatic breast cancer, they are looking hopefully toward the more than 24 targeted therapies in Phase II or Phase III trials for metastatic HER2-negative breast cancer.

Some clinicians also suggest Avastin, a mAb against VEGF, could find another spot in this expanding breast cancer armamentarium.

Existing treatment options include platinum drugs, capecitabine and Abraxane nab-paclitaxel from Celgene Corp.

"There are many active drugs available, and I think patients can still feel comfortable with their choices," said Generosa Grana, head of the division of hematology/oncology and director of the Cooper Cancer Institute.

She is most excited about Halaven eribulin mesylate from Eisai Co. Ltd., which FDA approved last

Read the full 1120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers